Navigation Links
State Food and Drug Administration Grants Approval to Sihuan Pharmaceutical for Clinical Trial of Innovative Drug -- Pinoxacin Hydrochloride
Date:2/22/2013

HONG KONG, Feb. 22, 2013 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Company"), a leading pharmaceutical company with the largest cardio-cerebral vascular ("CCV") drug franchise in China's prescription market, today announced that Pinoxacin Hydrochloride, a Category 1.1 new drug developed by the Company's innovative drug research and development team, received Approval for Clinical Studies from the State Food and Drug Administration. Phase I of clinical studies are set to begin in the first half of this year. It is the fourth Category 1 innovative drug for which the Company has received Approval for Clinical Studies.

Pinoxacin Hydrochloride is DPP-4 inhibitor class of oral hypoglycemic agents, a drug with a brand new structure for treating type II diabetes. It is clinically used to enhance the function of endogenous insulin for improving glycemic control, and long-term use can improve islet beta-cells function. Pre-clinical research has shown that DPP-4 inhibitors have potent in vitro and in vivo activities, a good selection profile, great stability and controllable quality, as well as better tolerance, with long-term administration showing a protective effect on pancreatic beta-cells. In addition, the DPP-4 inhibitor will not cause serious side effects such as weight gain and hypoglycaemia seen in traditional diabetes drugs. Pinoxacin Hydrochloride has good pharmacokinetic characteristics, high oral bioavailability, quick absorption, rapid onset and a longer duration. A once daily dosage is expected to keep the patients' symptoms under control. The advantages of Pinoxacin Hydrochloride have proven the drug's growth potential present in the market.

According to statistics from IMS, in 2011, the size of China's diabetes drug market was RMB 13.4 billion, one of the largest
'/>"/>

SOURCE Sihuan Pharmaceutical Holdings Group Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. U.S. FDA Grants Priority Review to Bayers Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases
2. TorkLaw Responds to FDA Warning Letter to St. Jude Medical Regarding Defective Heart Device; Now Representing Patients in 15 States
3. Fox News Medical Contributor Explains Study of Side Effects from Prostate-Cancer Treatments
4. United States Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
5. Statement from Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on the Front Page New York Times Story Regarding the Pre-emptive Strikes of Amgen/Genentech to Restrict Access to Affordable and Safe Biosimilars
6. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
7. Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
8. Virtual Ports Receives Patent Approvals in the United States and Japan
9. Amgen Backs States Efforts To Enact Biosimilar Legislation That Allows For Substitution And Supports Patient Safety
10. Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
11. Medbox, Inc. Sees Opportunity in Several New States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BOTHELL, Wash. , Sept. 23, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced two new additions to its Scientific Advisory Board.  ... and Anthony Davies , PhD. Dr. ...
(Date:9/22/2014)... BARCELONA, Spain , September 23, 2014 ... sponsors to meet health authorities, increasing rigor for trial ... The life sciences industry,s largest TMF survey to date ... sponsors that plan to provide auditors with remote access ... 32% of TMF owners surveyed in the ...
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 /PRNewswire/ ... is in mature stage. It is largely a ... endoscopy suite expansion. The mergers, acquisitions and partnerships ... Europe . This research service provides details ... competitive environment and pricing trends across the country. ...
Breaking Medicine Technology:BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Automated Endoscope Reprocessor Market Trends in Western Europe 2Automated Endoscope Reprocessor Market Trends in Western Europe 3
... RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity ... today that it has entered into a definitive ... Clinical Innovations, LLC ("Clinical"), to The Pritzker Group, ...  Terms of the transaction were not disclosed. ...
... Amira Pharmaceuticals, Inc. announced today that it has ... lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme ... a number of diseases including rheumatoid arthritis, glioblastoma, lung, ... pleased to announce that we have identified an orally ...
Cached Medicine Technology:RoundTable Healthcare Partners Announces Sale of Clinical Innovations, LLC to The Pritzker Group 2Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor 2
(Date:9/23/2014)... better screening strategies can lower the rate of false-positive ... on women. The many misperceptions about breast cancer screening ... and the need for new approaches and better education ... supplement to Journal of Women,s Health , a ... supplement is available free on the Journal of ...
(Date:9/23/2014)... National Institutes of Health has awarded $10.1 million in ... to explore the effects of sex in preclinical and ... females and males, and is a catalyst for considering ... overreliance on male subjects in preclinical research can obscure ... human studies. This progressive approach will result in greater ...
(Date:9/23/2014)... BLOOMINGTON, Ind. -- Contrary to what is often assumed ... a new study from The Kinsey Institute has found ... and are sexually active as often as singles without ... older children. , The study, "Dating and Sexual Behavior ... States," was published online in the Journal of ...
(Date:9/23/2014)... 2014 PM360, a leading health-marketing industry ... industry with their annual Trailblazer Awards on Thursday, September ... at Gotham Hall in New York City, are given ... talent and brands. , “This industry ... Stashower, CEO and Publisher of PM360. “We are happy ...
(Date:9/23/2014)... 2014 The University of Maryland Medical System ... Court to pay $3 million for negligence during the delivery ... anterior arm [shoulder dystocia occurs after the delivery of the ... mother’s pelvic bone]. , On September 5, ... Uriah Evans, et. al. v. University of Maryland Medical Systems ...
Breaking Medicine News(10 mins):Health News:Opportunities to reduce patient burden associated with breast cancer screening 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 2Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 3Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 4Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 5Health News:PM360 Magazine Announces Winners of 2014 Trailblazer Awards 6Health News:Toddler Awarded $3 Million in a Shoulder Dystocia Case Against University of Maryland Medical System with Help from Attorneys at Gilman & Bedigian LLC 2Health News:Toddler Awarded $3 Million in a Shoulder Dystocia Case Against University of Maryland Medical System with Help from Attorneys at Gilman & Bedigian LLC 3
... a boost from a surprising source: the 2009 H1N1 pandemic ... strain developed antibodies that are protective against a variety of ... the University of Chicago have found. The results were published ... "Our data shows that infection with the 2009 pandemic ...
... , , Reproductive medicine is one of ... there are announcements of medical ,firsts, new rulings by ... heated debate among practitioners in the field, ethicists, legislators, ... is the forum where more than 9,000 of the ...
... News) -- Race and ethnicity play major roles in whether ... with minorities much less likely to undergo colonoscopies than white ... play: where people live. Research by oncologist Dr. ... Davis Cancer Center found that location makes a big difference ...
... January 10, 2011 -- While most blood tests require shipping a ... days for the results, a new device invented by a team ... just a pinprick of blood in a portable device that provides ... big step in point-of-care diagnostics, where testing can be performed in ...
... News) -- The first study to focus solely on the ... Sept. 11, 2001 attacks on the World Trade Center finds ... of the 3,271 evacuees of the Twin Towers surveyed in ... at least one current post-traumatic stress symptom, while 15 percent ...
... be most useful for clinical decision-making in trials in which ... recent study published online January 7 in The ... has been increasing interest in the value of patient-reported symptom ... secondary endpoints in new trials. Both the World Health Organization ...
Cached Medicine News:Health News:Pandemic flu strain could point way to universal vaccine 2Health News:Pandemic flu strain could point way to universal vaccine 3Health News:ESHRE bridges East and West for its 2012 Congress in Istanbul 2Health News:Geography May Influence Colon Cancer Screening Rates 2Health News:Engineering team invents lab-on-a-chip for fast, inexpensive blood tests 2Health News:Many Survivors of World Trade Center Attacks Suffered PTSD: Study 2Health News:Quality of life measures in breast cancer clinical trials 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: